Objective: To assess the effectiveness of Wii sports-based strategy training on risk of falling, falls and quality of life in adults with idiopathic Parkinson's disease.
Design: Single blind, Randomised comparative trial.
Setting: Hospital and home.
Subjects: Diagnosed as idiopathic Parkinson's disease, Hoehn-Yahr stage 2.5 to 4, history of at least 3 falls in the last 3 months.
Intervention: Experimental group participated in 30-40 min of Wii training, 3 session/week for 12 weeks and control group participated for the same duration in traditional balance training. During each session both the group received 30 min of conventional physiotherapy.
Outcomes: Number of fallers, Fall rate, Berg balance scale, Timed up and go test, Parkinson's disease questionnaire 39, at baseline, 12 and 36 week after baseline.
Results: We randomised 192 participants. Participant's characteristics were similar between Wii and control group at base line, in age 69.7 ± 10, 68.5 ± 9.8, disease severity 3.43 ± 0.56, 3.42 ± 0.59, and fall rate 10.47 ± 15.78, 11.80 ± 18.95 (in mean ± SD). At 12 week 28%(27), 51%(49) & 36 week 45%(42), 60%(57) in Wii-group, control group fell at least once, respectively. Wii group improved more than control group at 12, 36 week in number of fallers (-23%, < 0.001) (-15%, < 0.039), fall rates -2.635(-5.38 to 0.112), -1.476(-5.09 to 2.142) (difference in mean, Confidence Interval) and bodily discomfort component of PDQ 39.
Conclusion: A 12 weeks exercise training using the Wii sports-based strategy decreases the number of fallers, fall rate, measures of risk of falling but did not alter the quality of life in adults with idiopathic Parkinson's disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/02692155221089030 | DOI Listing |
Hum Vaccin Immunother
December 2025
Research and Development, Infectious Disease, Moderna, Inc., Cambridge, MA, USA.
Safety, immunogenicity, and effectiveness of an mRNA-1273 50-μg booster were evaluated in adolescents (12-17 years), with and without pre-booster SARS-CoV-2 infection. Participants who had received the 2-dose mRNA-1273 100-µg primary series in the TeenCOVE trial (NCT04649151) were offered the mRNA-1273 50-μg booster. Primary objectives included safety and inference of effectiveness by establishing noninferiority of neutralizing antibody (nAb) responses after the booster compared with the nAb post-primary series of mRNA-1273 among young adults in COVE (NCT04470427).
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.
Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.
Transl Vis Sci Technol
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Purpose: This study investigates the association between visual function and retinal vasculature metrics, particularly perfusion capacity (PC), in eyes with idiopathic epiretinal membrane (iERM), using optical coherence tomography angiography (OCTA).
Methods: This retrospective study includes 30 eyes from 30 iERM patients who had surgery, with a three-month follow-up period. In addition, 28 eyes from 28 healthy individuals served as a control group.
Invest Ophthalmol Vis Sci
January 2025
Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Purpose: This study aimed to evaluate early-phase safety of subretinal application of AAVanc80.CAG.USH1Ca1 (OT_USH_101) in wild-type (WT) pigs, examining the effects of a vehicle control, low dose, and high dose.
View Article and Find Full Text PDFJAMA Pediatr
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.
Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!